22.11.2016 20:03:00
|
ARWR LOSS ALERT: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action- ARWR
NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Rosen Law Firm, reminds purchasers of Arrowhead Pharmaceuticals, Inc. securities (NASDAQ: ARWR) from May 11, 2015 through November 8, 2016, both dates inclusive (the "Class Period") of the important January 16, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Arrowhead investors under the federal securities laws.
To join the Arrowhead class action, go to http://www.rosenlegal.com/cases-997.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants made materially false and misleading statements and/or failed to disclose that: (1) ARC-520, one of Arrowhead's drug candidates for patients with chronic hepatitis B infection, was fatal at certain doses; (2) consequently, the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; (3) Arrowhead had overstated the approval prospects and commercial viability of ARC-520; and (4) as a result, Arrowhead's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-997.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com
Logo - http://photos.prnewswire.com/prnh/20160907/405060LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arwr-loss-alert-rosen-law-firm-reminds-arrowhead-pharmaceuticals-inc-investors-of-important-deadline-in-class-action--arwr-300367562.html
SOURCE Rosen Law Firm, P.A.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Arrowhead Pharmaceuticals Incmehr Nachrichten
25.11.24 |
Ausblick: Arrowhead Pharmaceuticals stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) | |
11.11.24 |
Erste Schätzungen: Arrowhead Pharmaceuticals stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) | |
07.08.24 |
Ausblick: Arrowhead Pharmaceuticals stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) | |
25.07.24 |
Erste Schätzungen: Arrowhead Pharmaceuticals öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |